1/1
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6 to 11 Years of Age with Severe Atopic Dermatitis
media
posted on 2023-09-12, 07:53 authored by Adis journals on behalf of, Michael J. Cork, Diamant Thaçi, Lawrence F. Eichenfield, Peter D. Arkwright, Zhen Chen, Ryan B. Thomas, Matthew P. Kosloski, Ariane Dubost-Brama, Randy Prescilla, Ashish Bansal, Noah Alexander LevitThe article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.
The above infographic and video represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
